Question explored with the scientific record
does ivermectin work for covid
The short version: the best evidence, including the largest and most recent meta-analyses, shows ivermectin does not meaningfully change COVID-19 outcomes.
The most comprehensive and recent meta-analysis, covering 40 randomized trials with over 23,000 participants, found ivermectin had no statistically significant effect on infection rates, mortality in hospitalized patients or outpatients, or adverse events [8]. A separate 2025 meta-analysis of 23 trials (over 12,000 people) also found no significant improvement in viral clearance, hospitalization duration, or symptom resolution [10]. The large ACTIV-6 platform trial, which tested repurposed drugs in outpatients, was designed to evaluate ivermectin but found no benefit on its primary outcomes [11].
Some earlier, smaller studies reported positive signals. A 2022 retrospective study of 423 hospitalized patients found faster PCR clearance and lower ICU step-up with ivermectin, but the mortality reduction was not statistically significant [1]. A 2021 Iraqi trial of 140 patients reported faster recovery and lower severe-case mortality when ivermectin was combined with doxycycline, but the severe-mortality difference also missed statistical significance [3]. These are the kinds of lower-quality, underpowered studies that the larger, more rigorous trials failed to replicate.
The evidence that does show benefit is almost entirely from studies with serious design weaknesses: retrospective designs, open-label treatment, small sample sizes, or combination therapy that makes it impossible to isolate ivermectin's effect [1, 3, 5, 7, 9]. The larger, blinded, placebo-controlled trials consistently show no benefit [2, 4, 6, 8, 10].
| Outcome | Ivermectin result | Source |
|---|---|---|
| Mortality (hospitalized) | No significant reduction (RR 0.94) | Meta-analysis of 22 RCTs [8] |
| Mortality (outpatients) | No significant reduction (RR 0.88) | Meta-analysis of 14 RCTs [8] |
| Prevention of infection | No significant reduction (RR 0.37, wide CI) | Meta-analysis of 4 RCTs [8] |
| Symptom resolution | No significant difference | Largest double-blind RCT [2] |
| Viral clearance | No significant improvement | Meta-analysis of 8 RCTs [10] |
| Adverse events | No significant increase | Meta-analysis of 7 RCTs [10] |
My call: ivermectin does not work for preventing or treating COVID-19. The best evidence, from large, well-designed randomized trials and comprehensive meta-analyses, shows no clinically meaningful benefit on any hard outcome. Confidence: high.
Sources used 11
-
Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study.
In a retrospective cohort of 423 hospitalized COVID-19 patients, ivermectin plus standard therapy was associated with faster PCR clearance and lower ICU step-up, but mortality reduction was not statistically significant.
DOI: 10.29309/tpmj/2022.29.09.6634 -
Ivermectin - an antiviral drug for the COVID-19 pandemic?
This narrative review concludes that ivermectin cannot be recommended for treating COVID-19 because robust trials showed no significant benefit in key clinical outcomes, although some lower-quality studies reported positive findings.
DOI: 10.12746/swrccc.v11i46.1141 -
Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq
In a randomized trial of 140 COVID-19 patients in Baghdad, adding ivermectin plus doxycycline to standard care shortened mean recovery time (10.61 vs 17.9 days) and reduced severe-case mortality (0/11 vs 6/22) and progression to critical disease (1/11 vs 7/22) compared with stan…
DOI: 10.22578/ijms.19.1.14 -
Clinical efficacy and safety of ivermectin (400 ug/kg, single dose) in patients with severe COVID-19: a randomized clinical trial
Among hospitalized adults with severe COVID-19, adding a single 400 μg/kg dose of ivermectin to standard care, compared with placebo, produced no significant difference in 21-day ICU admission, invasive mechanical ventilation, mortality, or adverse events.
DOI: 10.22354/24223794.1105 -
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
In a retrospective series of 320 high-risk outpatients with suspected or confirmed COVID-19 treated with empiric multidrug therapy, hospitalization occurred in 6 (1.9%) and death in 1 (0.3%), suggesting low event rates but lacking a control group.
DOI: 10.31083/j.rcm.2020.04.260 -
Efficacy and safety of ivermectin in patients with mild and moderate COVID-19: A randomized controlled trial
Adding a single dose of ivermectin to standard treatment did not significantly change hospital stay, ICU admission, ICU stay, in-hospital mortality, or adverse drug reactions in hospitalized adults with mild-to-moderate COVID-19.
DOI: 10.4103/1995-7645.364007 -
Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19)
Early ambulatory multidrug therapy for high-risk COVID-19 patients reduced hospitalization by about 88% and death by about 75% versus expected regional rates.
DOI: 10.23958/ijirms/vol06-i03/1100 -
The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
In 40 RCTs (23,243 participants), ivermectin showed no statistically significant preventive or therapeutic benefit for SARS-CoV-2 infection, with no significant effects on infection rate, mortality, adverse events, or most secondary outcomes.
DOI: 10.1186/s12879-026-13195-9 -
Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers
In a cluster-randomized trial of 254 outpatients with mild COVID-19 in Tucumán, Argentina, oral ivermectin plus symptomatic treatment was associated with significantly higher medical discharge at 28 days and greater symptom reduction from days 5–9 than symptomatic treatment alon…
DOI: 10.33448/rsd-v11i8.30844 -
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole
An up-to-date meta-analysis of 23 randomized trials (n = 12,345) evaluating ivermectin and mebendazole for COVID-19 found no statistically significant improvement in viral clearance, hospitalization duration, or symptom resolution overall, although some individual studies sugges…
DOI: 10.3390/antibiotics14050459 -
ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19
ACTIV-6 is described as a multicenter, double-blind, placebo-controlled, randomized, decentralized platform trial designed to evaluate repurposed medicines for reducing symptoms and preventing disease progression in non-hospitalized adults with mild-to-moderate COVID-19.
DOI: 10.1017/cts.2023.644